Taurine is a liver X receptor-α ligand and activates transcription of key genes in the reverse cholesterol transport without inducing hepatic lipogenesis

Molecular Nutrition and Food Research

Volumn 56, Issue 6, 2012, Pages 900-911

  Hoang, Minh Hien ^a   Jia, Yaoyao ^a   Jun, Hee jin ^a   Lee, Ji Hae ^a   Hwang, Kwang Yeon ^a   Choi, Dal Woong ^a   Um, Soo Jong ^b   Lee, Boo Yong ^c   You, Sang Guan ^d   Lee, Sung Joon ^a  

^a Korea University   (South Korea)

^b Sejong University   (South Korea)

^c CHA University   (South Korea)

^d Gangneung Wonju National University   (South Korea)

Author keywords

Cholesterol; Insig 2a; LXR ; SREBP 1c; Taurine

Indexed keywords

ABC TRANSPORTER; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; INSIG2 PROTEIN, HUMAN; ISOPROTEIN; LIGAND; LIVER X RECEPTOR; MEMBRANE PROTEIN; MESSENGER RNA; ORPHAN NUCLEAR RECEPTOR; RECOMBINANT PROTEIN; SIGNAL PEPTIDE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TAURINE;

ANIMAL; ARTICLE; CELL LINE; CRICETULUS; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; HUMAN; INTESTINE CELL; LIPOLYSIS; LIVER; MACROPHAGE; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; CHOLESTEROL; CRICETINAE; CRICETULUS; ENTEROCYTES; GENE EXPRESSION REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; LIPOLYSIS; LIVER; MACROPHAGES; MEMBRANE PROTEINS; ORPHAN NUCLEAR RECEPTORS; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TAURINE;

EID: 84862585237     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201100611     Document Type: Article

References (52)

1. Huxtable, R. J., Physiological actions of taurine. Physiol. Rev. 1992, 72, 101-163.
2. Wright, C. E., Tallan, H. H., Lin, Y. Y., Gaull, G. E., Taurine: biological update. Annu. Rev. Biochem. 1986, 55, 427-453.
3. Gaull, G. E., Taurine in pediatric nutrition: review and update. Pediatrics 1989, 83, 433-442.
4. Yamori, Y., Liu, L., Ikeda, K., Miura, A. et al., Distribution of twenty-four hour urinary taurine excretion and association with ischemic heart disease mortality in 24 populations of 16 countries: results from the WHO-CARDIAC study. Hypertens. Res. 2001, 24, 453-457.
5. Yanagita, T., Han, S. Y., Hu, Y., Nagao, K. et al., Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells. Lipids Health Dis. 2008, 7, 38--43.
6. Mochizuki, H., Oda, H., Yokogoshi, H., Increasing effect of dietary taurine on the serum HDL-cholesterol concentration in rats. Biosci. Biotech. Bioch. 1998, 62, 578-579.
7. Yokogoshi, H., Mochizuki, H., Nanami, K., Hida, Y. et al., Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high-cholesterol diet. J. Nutr. 1999, 129, 1705-1712.
8. Whitney, K. D., Watson, M. A., Goodwin, B., Galardi, C. M. et al., Liver X receptor (LXR) regulation of the LXRalpha gene in human macrophages. J. Biol. Chem. 2001, 276, 43509-43515.
9. Levin, N., Bischoff, E. D., Daige, C. L., Thomas, D. et al., Macrophage liver x receptor is required for antiatherogenic activity of LXR agonists. Arterioscl. Throm. Vas. 2005, 25, 135-142.
10. Naik, S. U., Wang, X., Da Silva, J. S., Jaye, M. et al., Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006, 113, 90-97.
11. Joseph, S. B., McKilligin, E., Pei, L., Watson, M. A. et al., Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 2002, 99, 7604-7609.
12. Repa, J. J., Berge, K. E., Pomajzl, C., Richardson, J. A. et al., Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 2002, 277, 18793-18800.
13. Berge, K. E., Tian, H., Graf, G. A., Yu, L. et al., Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000, 290, 1771-1775.
14. Geyeregger, R., Zeyda, M., Stulnig, T. M., Liver X receptors in cardiovascular and metabolic disease. Cell Mol. Life Sci. 2006, 63, 524-539.
15. Peet, D. J., Turley, S. D., Ma, W., Janowski, B. A. et al., Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93, 693-704.
16. Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A. et al., Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 1997, 272, 3137-3140.
17. Crestani, M., Sadeghpour, A., Stroup, D., Galli, G., Chiang, J. Y., Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (CYP7A) by nuclear hormone receptors. J. Lipid Res. 1998, 39, 2192-2200.
18. Chiang, J. Y., Kimmel, R., Stroup, D., Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene 2001, 262, 257-265.
19. Song, C., Hiipakka, R. A., Liao, S., Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs. Steroids 2000, 65, 423-427.
20. Jia, Y., Bhuiyan, M. J. H., Jun, H. J., Lee, J. H. et al., Ursolic acid is a PPAR-alpha agonist that regulates hepatic lipid metabolism. Bioorg. Med. Chem. Lett. 2011, 21, 5876-5880.
21. Huang, T. H., Razmovski-Naumovski, V., Salam, N. K., Duke, R. K. et al., A novel LXR-alpha activator identified from the natural product Gynostemma pentaphyllum. Biochem. Pharmacol. 2005, 70, 1298-1308.
22. Svensson, S., Ostberg, T., Jacobsson, M., Norstrom, C. et al., Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. EMBO J. 2003, 22, 4625-4633.
23. Lii, J. H., Allinger, N. L., Molecular mechanics-the Mm3 force-field for hydrocarbons .3. The van der Waals potentials and crystal data for aliphatic and aromatic-hydrocarbons. J. Am. Chem. Soc. 1989, 111, 8576-8582.
24. Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A. et al., Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
25. Hozumi, Y., Kawano, M., Jordan, V. C., In vitro study of the effect of raloxifene on lipid metabolism compared with tamoxifen. Eur. J. Endocrinol. 2000, 143, 427-430.
26. Folch, J., Lees, M., Sloane Stanley, G. H., A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226, 497-509.
27. Hoang, M. H., Houng, S. J., Jun, H. J., Lee, J. H. et al., Barley intake induces bile acid excretion by reduced expression of intestinal ASBT and NPC1L1 in C57BL/6J mice. J. Agric. Food Chem. 2011, 59, 6798-6805.
28. Goodwin, B., Watson, M. A., Kim, H., Miao, J. et al., Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-alpha. Mol. Endocrinol. 2003, 17, 386-394.
29. Yellaturu, C. R., Deng, X., Park, E. A., Raghow, R., Elam, M. B., Insulin enhances the biogenesis of nuclear sterol regulatory element-binding protein (SREBP)-1c by posttranscriptional down-regulation of Insig-2A and its dissociation from SREBP cleavage-activating protein (SCAP).SREBP-1c complex. J. Biol. Chem. 2009, 284, 31726-31734.
30. Yellaturu, C. R., Deng, X., Cagen, L. M., Wilcox, H. G. et al., Insulin enhances post-translational processing of nascent SREBP-1c by promoting its phosphorylation and association with COPII vesicles. J. Biol. Chem. 2009, 284, 7518-7532.
31. Rayner, K. J., Suarez, Y., Davalos, A., Parathath, S. et al., MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010, 328, 1570-1573.
32. Aravindhan, K., Webb, C. L., Jaye, M., Ghosh, A. et al., Assessing the effects of LXR agonists on cellular cholesterol handling: a stable isotope tracer study. J. Lipid Res. 2006, 47, 1250-1260.
33. Gelissen, I. C., Harris, M., Rye, K. A., Quinn, C. et al., ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 534-540.
34. Yoon, H. S., Ju, J. H., Kim, H., Lee, J. et al., Lactobacillus rhamnosus BFE 5264 and Lactobacillus plantarum NR74 promote cholesterol excretion through the up-regulation of ABCG5/8 in Caco-2 cells. Probiotics Antimicro. Prot. 2011, 3, 194-203.
35. Kuipers, F., Grefhorst, A., Elzinga, B. M., Voshol, P. J. et al., Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 2002, 277, 34182-34190.
36. Tontonoz, P., Joseph, S. B., Laffitte, B. A., Patel, P. H. et al., Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 2002, 277, 11019-11025.
37. Brown, M. S., Goldstein, J. L., A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA 1999, 96, 11041-11048.
38. Yabe, D., Brown, M. S., Goldstein, J. L., Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc. Natl. Acad. Sci. USA 2002, 99, 12753-12758.
39. Engelking, L. J., Kuriyama, H., Hammer, R. E., Horton, J. D. et al., Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J. Clin. Invest. 2004, 113, 1168-1175.
40. Ringseis, R., Eder, K., Regulation of genes involved in lipid metabolism by dietary oxidized fat. Mol. Nutr. Food Res. 2011, 55, 109-121.
41. Hubbert, M. L., Zhang, Y., Lee, F. Y., Edwards, P. A., Regulation of hepatic Insig-2 by the farnesoid X receptor. Mol. Endocrinol. 2007, 21, 1359-1369.
42. Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G. et al., Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284, 1365-1368.
43. Adams, C. M., Reitz, J., De Brabander, J. K., Feramisco, J. D. et al., Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and insigs. J. Biol. Chem. 2004, 279, 52772-52780.
44. Stipanuk, M. H., Role of the liver in regulation of body cysteine and taurine levels: a brief review. Neurochem. Res. 2004, 29, 105-110.
45. Hsu, C. C., Huang, C. N., Hung, Y. C., Yin, M. C., Five cysteine-containing compounds have antioxidative activity in Balb/cA mice. J. Nutr. 2004, 134, 149-152.
46. Seidel, J. C., Nath, N., Harper, A. E., Diet and cholesterolemia. V. Effects of sulfur-containing amino acids and protein. J. Lipid Res. 1960, 1, 474-481.
47. Ntambi, J. N., Miyazaki, M., Dobrzyn, A., Man, W. C. et al., Stearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and -independent mechanisms. J. Biol. Chem. 2004, 279, 25164-25171.
48. Miao, B., Zondlo, S., Gibbs, S., Cromley, D. et al., Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J. Lipid Res. 2004, 45, 1410-1417.
49. Albers, M., Blume, B., Schlueter, T., Wright, M. B. et al., A novel principle for partial agonism of liver X receptor ligands-competitive recruitment of activators and repressors. J. Biol. Chem. 2006, 281, 4920-4930.
50. Cantafora, A., Yan, C. C., Sun, Y., Masella, R., Effects of taurine on microsomal enzyme activities involved in liver lipid metabolism of Wistar rats. Adv. Exp. Med. Biol. 1994, 359, 99-110.
51. Schaffer, S., Solodushko, V., Azuma, J., Taurine-deficient cardiomyopathy: role of phospholipids, calcium and osmotic stress. Adv. Exp. Med. Biol. 2000, 483, 57-69.
52. Ghandforoush-Sattari, M., Mashayekhi, S., Pharmacokinetics of oral taurine in healthy volunteers. Pharm. World Sci. 2008, 30, 724-724.